Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.78 and traded as high as $2.20. Heron Therapeutics shares last traded at $2.15, with a volume of 1,147,607 shares traded.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Needham & Company LLC restated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th.
Check Out Our Latest Stock Report on Heron Therapeutics
Heron Therapeutics Price Performance
The company's 50-day simple moving average is $2.13 and its 200 day simple moving average is $1.79. The firm has a market cap of $354.93 million, a P/E ratio of -12.94 and a beta of 1.39.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. Analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On Heron Therapeutics
Institutional investors have recently made changes to their positions in the company. Nicolet Advisory Services LLC bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $25,000. RFP Financial Group LLC bought a new stake in shares of Heron Therapeutics in the 1st quarter worth about $26,000. Argent Advisors Inc. bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $31,000. Focus Partners Wealth bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $31,000. Finally, State of Wyoming lifted its holdings in shares of Heron Therapeutics by 573.5% in the 4th quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 25,321 shares during the last quarter. Institutional investors own 80.01% of the company's stock.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
